Rhinitis in the Elderly: The Role of Vitamin D
"Rhinitis in the Elderly: A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study of the Effect of Vitamin D Supplementation on Nasal Symptoms and Rhinitis Related Quality of Life"
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Bryn Mawr, Pennsylvania, United States, 19010
- Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.
-
Bryn Mawr, Pennsylvania, United States, 19010
- Rohr and Columbo Asthma, Allergy and Immunology Specialists
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects 65 years old and older with perennial and/or nonallergic rhinitis
Exclusion Criteria:
- Current smokers, digoxin, liver disease, anticoagulants (except for aspirin), planning a surgical procedure during the study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Vitamin D
Vitamin D 4,000 I.U. orally
|
Cross-over design
|
|
Placebo Comparator: Placebo
Placebo orally
|
Cross-over design
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Effect of vitamin D on rhinitis symptoms and rhinitis related quality of life measured by standardized questionnaire.
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Associations between baseline serum vitamin D and subjects' demographics and treatment
Time Frame: 6 weeks
|
Demographics include age, body mass index, duration of rhinitis, and presence of asthma.
Treatment include drugs utilized for treatment of rhinitis expressed as total medication score.
|
6 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety of vitamin D supplementation in the elderly
Time Frame: 6 weeks
|
Will assess serum vitamin D and calcium levels as well as possible side effects from the treatment as reported by the study subjects.
No specific tool would be used.
|
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Michele Columbo, M.D., Rohr and Columbo Associates
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- F/N-R14-3326B
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.